5,897 reports of this reaction
2.8% of all TADALAFIL reports
#5 most reported adverse reaction
DEATH is the #5 most commonly reported adverse reaction for TADALAFIL, manufactured by United Therapeutics Corporation. There are 5,897 FDA adverse event reports linking TADALAFIL to DEATH. This represents approximately 2.8% of all 207,750 adverse event reports for this drug.
TADALAFIL has an overall safety score of 85 out of 100. Patients taking TADALAFIL who experience death should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEATH is a less commonly reported adverse event for TADALAFIL, but still significant enough to appear in the safety profile.
In addition to death, the following adverse reactions have been reported for TADALAFIL:
The following drugs have also been linked to death in FDA adverse event reports:
DEATH has been reported as an adverse event in 5,897 FDA reports for TADALAFIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEATH accounts for approximately 2.8% of all adverse event reports for TADALAFIL, making it a notable side effect.
If you experience death while taking TADALAFIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.